Display options
Cite
Kawamura K, Ichikado K, Takaki M, et al. Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. Springerplus. 2016;5(1):1193doi: 10.1186/s40064-016-2866-1.
Kawamura, K., Ichikado, K., Takaki, M., Sakata, Y., Yasuda, Y., Shingu, N., Tanaka, A., Hisanaga, J., Eguchi, Y., Anan, K., Nitawaki, T., & Suga, M. (2016). Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. SpringerPlus, 5(1), 1193. https://doi.org/10.1186/s40064-016-2866-1
Kawamura, Kodai, et al. "Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis." SpringerPlus vol. 5,1 (2016): 1193. doi: https://doi.org/10.1186/s40064-016-2866-1
Kawamura K, Ichikado K, Takaki M, Sakata Y, Yasuda Y, Shingu N, Tanaka A, Hisanaga J, Eguchi Y, Anan K, Nitawaki T, Suga M. Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. Springerplus. 2016 Jul 28;5(1):1193. doi: 10.1186/s40064-016-2866-1. eCollection 2016. PMID: 27516931; PMCID: PMC4963331.
Copy Download .nbib Format: NLM
Share it on

Springerplus. 2016 Jul 28;5(1):1193. doi: 10.1186/s40064-016-2866-1. eCollection 2016.

Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis.

SpringerPlus

Kodai Kawamura, Kazuya Ichikado, Makoto Takaki, Yoshihiko Sakata, Yuko Yasuda, Naoki Shingu, Aoi Tanaka, Jyunpei Hisanaga, Yoshitomo Eguchi, Keisuke Anan, Tatuya Nitawaki, Moritaka Suga

Affiliations

  1. Division of Respiratory Medicine, Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc., Saiseikai Kumamoto Hospital, Kumamoto, Kumamoto 861-4193 Japan.

PMID: 27516931 PMCID: PMC4963331 DOI: 10.1186/s40064-016-2866-1

Abstract

PURPOSE: Acute respiratory distress syndrome is a life-threatening form of respiratory failure without an established pharmacological treatment. Recently, macrolides have been found to be beneficial in cases of acute lung injury, but evidence is limited.

MATERIALS AND METHODS: This single-centre retrospective cohort evaluation of hospitalized patients with sepsis-associated acute respiratory distress syndrome aimed to assess the impact of azithromycin on clinical outcomes by using a propensity score analysis. All data were collected prospectively as part of ongoing research on high-resolution computed tomography of acute respiratory distress syndrome. The primary outcome was 60-day mortality; the secondary outcome was the number of ventilator-free days.

RESULTS: Twenty-nine of 125 patients with sepsis-associated acute respiratory distress syndrome (23.2 %) received azithromycin within 24 h after acute respiratory distress syndrome diagnosis. After adjusting for potentially confounding covariates, azithromycin use was associated with lower 60-day mortality (hazard ratio, 0.31; 95 % confidence interval, 0.11-082; P = 0.02) and a shorter time to successful discontinuation of mechanical ventilation.

CONCLUSIONS: Azithromycin use was associated with decreased mortality and ventilator dependency in patients with sepsis-associated acute respiratory distress syndrome. Further well-designed prospective studies are needed.

Keywords: ARDS; Azithromycin; Macrolide; Prognosis; Propensity score; Ventilator-free days

References

  1. Chest. 2004 Feb;125(2 Suppl):41S-50S; quiz 51S - PubMed
  2. Nihon Kokyuki Gakkai Zasshi. 2010 Oct;Suppl:1-101 - PubMed
  3. Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24 - PubMed
  4. Intensive Care Med. 1999 Nov;25(11):1259-66 - PubMed
  5. N Engl J Med. 2005 Oct 20;353(16):1685-93 - PubMed
  6. JAMA. 2012 Jun 20;307(23):2526-33 - PubMed
  7. Clin Microbiol Rev. 2010 Jul;23(3):590-615 - PubMed
  8. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):853-7 - PubMed
  9. Intensive Care Med. 2010 Apr;36(4):612-20 - PubMed
  10. Am J Respir Crit Care Med. 2002 Jun 1;165(11):1551-6 - PubMed
  11. N Engl J Med. 2015 Apr 2;372(14):1312-23 - PubMed
  12. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72 - PubMed
  13. Respir Res. 2013 May 10;14:52 - PubMed
  14. Nature. 2000 Sep 14;407(6801):258-64 - PubMed
  15. Am J Respir Cell Mol Biol. 2000 Apr;22(4):401-4 - PubMed
  16. J Inflamm (Lond). 2011 Jul 07;8:17 - PubMed
  17. Crit Care. 2013 Jun 20;17(3):R111 - PubMed
  18. Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L514-21 - PubMed
  19. J Antimicrob Chemother. 2014 Apr;69(4):1111-8 - PubMed
  20. Chest. 2008 May;133(5):1120-7 - PubMed
  21. JAMA Intern Med. 2014 Dec;174(12):1894-901 - PubMed
  22. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):454-62 - PubMed
  23. Chest. 1992 Jun;101(6):1644-55 - PubMed
  24. Crit Care Med. 2006 Mar;34(3):871-7 - PubMed
  25. Chest. 2012 May;141(5):1153-9 - PubMed
  26. Clin Infect Dis. 2012 Aug;55(3):371-80 - PubMed
  27. Eur Respir J. 2009 Jan;33(1):153-9 - PubMed
  28. Radiology. 2006 Jan;238(1):321-9 - PubMed
  29. Crit Care Med. 2010 Sep;38(9):1773-85 - PubMed
  30. BMJ Open. 2012 Mar 01;2(2):e000545 - PubMed
  31. Crit Care Med. 2014 Feb;42(2):420-32 - PubMed

Publication Types